BioIVT, a provider of mission-critical biological specimens and value-added services, completed the acquisition of Cypex, a renowned manufacturer of recombinant xenobiotic metabolizing enzymes. Financial terms were not disclosed. "We are delighted that the Cypex team is joining BioIVT, bringing with them not only their market-leading products, but also their in vitro drug metabolism technology expertise. The acquisition of Cypex enhances BioIVT's product portfolio, ensuring that we continue to meet all our biopharmaceutical customers' research requirements for their entire R&D pipeline," Richard Haigh, BioIVT CEO.